RiboScreenTM Technology Delivers Small-Molecule Ribodrugs to Convert Ribosomal Proteins into Molecular Valves for Tailored Protein Production Levels in Rare and Prevalent Disease †
Authors:
- Genevieve EdoborGEGenevieve Edobor
- Ronald HuberRHRonald Huber
- Christoph ReiterCRChristoph Reiter
- Hanna GerckeHGHanna Gercke
- Niklas KaeferNKNiklas Kaefer
- Elli KronsteinerEKElli Kronsteiner
- Bjoern WimmerBWBjoern Wimmer
- Marlies WimmerMWMarlies Wimmer
- Thomas KarlTKThomas Karl
- Mark RinnerthalerMark Rinnerthaler
- Jan KraußJKJan Krauß
- Heinrich KrobathHKHeinrich Krobath
Open Access
- 23 June 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1419
Abstract
Across all kingdoms of life, ribosomes are indispensable molecular machines that translate genetic information into the proteome of living cells. The fundamental catalytic centers of the ribosome, constructed primarily from ribosomal RNA (rRNA), exhibit remarkable conservation between the major domains of life. The ribosome’s A-site deciphers the mRNA’s triplet code, while the P-site synthesizes the growing protein chain and the E-site provides exit for deacylated tRNA; a distinct tunnel facilitates nascent polypeptide export. While the conservation of ribosomal proteins is less pronounced between bacteria and eukaryotes, striking homology exists from simple eukaryotes to humans. Ribosomal proteins were traditionally viewed mainly as scaffolding agents, steering rRNA folding during ribosome biogenesis and maintaining structural stability during translation. However, since the early 2000s, advances in structural and functional ribosome analysis have ushered in a more nuanced paradigm: ribosomes are no longer considered uniform machines. Instead, an array of rRNA and ribosomal protein modifications generates a spectrum of ribosome populations capable of specialized translation. RiboScreenTM technology leverages this regulatory potential of individual ribosomal proteins, enabling deliberate modulation of target protein output and representing a promising tool for correcting dysregulated protein expression involved in rare and common diseases. This review will first introduce relevant aspects of ribosome biology and then showcase the tools of this new technology. Finally, we report examples for the delivery of small molecules to target ribosomal proteins for tailored restoration of protein production levels in rare and prevalent diseases.Keywords
Funding Information
- Land Salzburg (P/147200/30)
This publication has 494 references indexed in Scilit:
- The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategiesMolecular Oncology, 2025
- The translatome of glioblastomaMolecular Oncology, 2024
- Decoding the ribosome's hidden language: rRNA modifications as key players in cancer dynamics and targeted therapiesClinical and Translational Medicine, 2024
- Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense VariantsJAMA Dermatology, 2022
- Translational Control under Stress: Reshaping the TranslatomeBioEssays, 2019
- Comparison of preribosomal RNA processing pathways in yeast, plant and human cells – focus on coordinated action of endo‐ and exoribonucleasesFEBS Letters, 2017
- TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next DecadeHuman Mutation, 2014
- Translation elongation can control translation initiation on eukaryotic mRNAsThe EMBO Journal, 2013
- Birth, life and death of nascent polypeptide chainsBiotechnology Journal, 2011
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004